{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:45:12Z","timestamp":1774536312113,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170215"],"award-info":[{"award-number":["82170215"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870144"],"award-info":[{"award-number":["81870144"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970161"],"award-info":[{"award-number":["81970161"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015956","name":"Special Project for Research and Development in Key areas of Guangdong Province","doi-asserted-by":"publisher","award":["2019B020236004"],"award-info":[{"award-number":["2019B020236004"]}],"id":[{"id":"10.13039\/501100015956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00277-023-05361-9","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T20:28:46Z","timestamp":1689884926000},"page":"2865-2877","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study"],"prefix":"10.1007","volume":"102","author":[{"given":"Jiapei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieyu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqiu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoyang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qifa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9485-0249","authenticated-orcid":false,"given":"Hua","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"issue":"3","key":"5361_CR1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1182\/blood-2014-01-514786","volume":"124","author":"SG Holtan","year":"2014","unstructured":"Holtan SG, Pasquini M, Weisdorf DJ (2014) Acute graft-versus-host disease: a bench-to-bedside update. Blood 124(3):363\u2013373","journal-title":"Blood"},{"issue":"1","key":"5361_CR2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","volume":"119","author":"M Jagasia","year":"2012","unstructured":"Jagasia M, Arora M, Flowers MED, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang M-J, Antin JH, Bolwell BJ, Bredeson C, Cahn J-Y, Cairo M, Gale RP, Gupta V, Lee SJ, Litzow M, Weisdorf DJ, Horowitz MM, Hahn T (2012) Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 119(1):296\u2013307","journal-title":"Blood"},{"issue":"2","key":"5361_CR3","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/bmt.2013.107","volume":"49","author":"T Ruutu","year":"2014","unstructured":"Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, Dazzi F, Dreger P, Duarte R, Finke J, Garderet L, Greinix H, Holler E, Kroeger N, Lawitschka A, Mohty M, Nagler A, Passweg J, Ringden O, Socie G, Sierra J, Sureda A, Wiktor-Jedrzejczak W, Madrigal A, Niederwieser D, European Grp Blood M, European LeukemiaNet ELN (2014) Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplantation 49(2):168\u2013173","journal-title":"Bone Marrow Transplantation"},{"issue":"8","key":"5361_CR4","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","volume":"18","author":"PJ Martin","year":"2012","unstructured":"Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, Litzow MR, Nieto Y, Savani BN, Schriber JR, Shaughnessy PJ, Wall DA, Carpenter PA (2012) First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American society of blood and marrow transplantation. Biol Blood Marrow Transplant 18(8):1150\u20131163","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"5361_CR5","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1182\/blood-2006-12-041889","volume":"109","author":"HJ Deeg","year":"2007","unstructured":"Deeg HJ (2007) How I treat refractory acute GVHD. Blood 109(10):4119\u20134126","journal-title":"Blood"},{"key":"5361_CR6","doi-asserted-by":"publisher","first-page":"601953","DOI":"10.1155\/2011\/601953","volume":"2011","author":"JR Westin","year":"2011","unstructured":"Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Anderlini P, Rondon G, Andersson BS, Champlin R, Couriel DR (2011) Steroid-refractory acute GVHD: predictors and outcomes. Adv Hematol 2011:601953\u2013601953","journal-title":"Adv Hematol"},{"issue":"5","key":"5361_CR7","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41375-020-0804-2","volume":"34","author":"F Malard","year":"2020","unstructured":"Malard F, Huang X-J, Sim JPY (2020) Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. Leukemia 34(5):1229\u20131240","journal-title":"Leukemia"},{"issue":"5","key":"5361_CR8","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1182\/blood-2016-09-738625","volume":"129","author":"G Socie","year":"2017","unstructured":"Socie G, Vigouroux S, Yakoub-Agha I, Bay J-O, Fuerst S, Bilger K, Suarez F, Michallet M, Bron D, Gard P, Medeghri Z, Lehert P, Lai C, Corn T, Vernant J-P (2017) A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD. Blood 129(5):643\u2013649","journal-title":"Blood"},{"issue":"6","key":"5361_CR9","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/bmt.2017.35","volume":"52","author":"GM Dotoli","year":"2017","unstructured":"Dotoli GM, De Santis GC, Orellana MD, de Lima PK, Caruso SR, Fernandes TR, Rensi Colturato VA, Kondo AT, Hamerschlak N, Simoes BP, Covas DT (2017) Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III\/IV after hematopoietic stem cell transplantation. Bone Marrow Transplant 52(6):859\u2013862","journal-title":"Bone Marrow Transplant"},{"key":"5361_CR10","doi-asserted-by":"crossref","unstructured":"De Jong CN, Saes L, Klerk CPW, Van der Klift M, Cornelissen JJ, Broers AEC (2017) Etanercept for steroid-refractory acute graft-versus-host disease: a single center experience. Plos One 12(10):e0187184","DOI":"10.1371\/journal.pone.0187184"},{"issue":"12","key":"5361_CR11","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/sj.bmt.1703737","volume":"30","author":"G Massenkeil","year":"2002","unstructured":"Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dorken B, Arnold R (2002) Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 30(12):899\u2013903","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"5361_CR12","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","volume":"382","author":"R Zeiser","year":"2020","unstructured":"Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socie G, Grp RT (2020) Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med 382(19):1800\u20131810","journal-title":"N Engl J Med"},{"issue":"10","key":"5361_CR13","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/leu.2015.212","volume":"29","author":"R Zeiser","year":"2015","unstructured":"Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Luebbert M, Waesch R, Scheid C, Stoelzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Graeff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kroeger N, Passweg J, Halter J, Socie G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N (2015) Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29(10):2062\u20132068","journal-title":"Leukemia"},{"issue":"1","key":"5361_CR14","doi-asserted-by":"publisher","first-page":"8501","DOI":"10.1038\/s41598-021-88080-3","volume":"11","author":"B Zhang","year":"2021","unstructured":"Zhang B, Chen L, Zhou J, Zu Y, Gui R, Li Z, Wang J, Yu F, Zhang Y, Zhao H, Ji Z, Song Y (2021) Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia. Sci Rep 11(1):8501","journal-title":"Sci Rep"},{"issue":"20","key":"5361_CR15","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/blood.2020004823","volume":"135","author":"M Jagasia","year":"2020","unstructured":"Jagasia M, Perales M-A, Schroeder MA, Ali H, Shah NN, Chen Y-B, Fazal S, Dawkins FW, Arbushites MC, Tian C, Connelly-Smith L, Howell MD, Khoury HJ, Grp RS (2020) Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood 135(20):1739\u20131749","journal-title":"Blood"},{"issue":"4","key":"5361_CR16","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1365-2141.2005.05631.x","volume":"130","author":"M Schmidt-Hieber","year":"2005","unstructured":"Schmidt-Hieber M, Fietz T, Knauf W, Uharek L, Hopfenmuller W, Thiel E, Blau IW (2005) Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br J Haematol 130(4):568\u2013574","journal-title":"Br J Haematol"},{"key":"5361_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.trim.2016.08.009","volume":"39","author":"SR Jaiswal","year":"2016","unstructured":"Jaiswal SR, Zaman S, Chakrabarti A, Sehrawat A, Bansal S, Gupta M, Chakrabarti S (2016) T cell costimulation blockade for hyperacute steroid refractory graft versus-host disease in children undergoing haploidentical transplantation. Transpl Immunol 39:46\u201351","journal-title":"Transpl Immunol"},{"issue":"8","key":"5361_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/ajh.25839","volume":"95","author":"S-N Liu","year":"2020","unstructured":"Liu S-N, Zhang X-H, Xu L-P, Wang Y, Yan C-H, Chen H, Chen Y-H, Han W, Wang F-R, Wang J-Z, Liu K-Y, Huang X-J, Mo X-D (2020) Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: updated experience from a large-scale study. Am J Hematol 95(8):927\u2013936","journal-title":"Am J Hematol"},{"issue":"5","key":"5361_CR19","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1016\/j.transproceed.2011.03.044","volume":"43","author":"JZ Wang","year":"2011","unstructured":"Wang JZ, Liu KY, Xu LP, Liu DH, Han W, Chen H, Chen YH, Zhang XH, Zhao T, Wang Y, Huang XJ (2011) Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-Mismatched\/Haploidentical hematopoietic stem cell transplantation. Transpl Proc 43(5):1928\u20131933","journal-title":"Transpl Proc"},{"issue":"2","key":"5361_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.bbmt.2019.10.031","volume":"26","author":"F-F Tang","year":"2020","unstructured":"Tang F-F, Cheng Y-F, Xu L-P, Zhang X-H, Yan C-H, Han W, Chen Y-H, Huang X-J, Wang Y (2020) Basiliximab as treatment for steroid-refractory acute graft-versus-host disease in pediatric patients after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 26(2):351\u2013357","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"5361_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/ejh.12691","volume":"97","author":"G Chakupurakal","year":"2016","unstructured":"Chakupurakal G, Garcia-Marquez MA, Shimabukuro-Vornhagen A, Theurich S, Holtick U, Hallek M, Scheid C, von Bergwelt-Baildon M (2016) Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody. Eur J Haematol 97(2):121\u2013127","journal-title":"Eur J Haematol"},{"issue":"1","key":"5361_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-022-01240-4","volume":"15","author":"K Zhao","year":"2022","unstructured":"Zhao K, Lin R, Fan Z, Chen X, Wang Y, Huang F, Xu N, Zhang X, Zhang X, Xuan L, Wang S, Lin D, Deng L, Nie D, Weng J, Li Y, Zhang X, Li Y, Xiang AP, Liu Q (2022) Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J Hematol Oncol 15(1):22","journal-title":"J Hematol Oncol"},{"issue":"1","key":"5361_CR23","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12916-022-02479-x","volume":"20","author":"X Xu","year":"2022","unstructured":"Xu X, Fan Z, Wang Y, Huang F, Xu Y, Sun J, Xu N, Deng L, Li X, Liang X, Luo X, Shi P, Liu H, Chen Y, Tu S, Huang X, Liu Q, Xuan L (2022) Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial. Bmc Med 20(1):282","journal-title":"Bmc Med"},{"issue":"2","key":"5361_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s15010-018-01265-3","volume":"47","author":"H Jin","year":"2019","unstructured":"Jin H, Fan Z, Huang F, Chai Y, Xuan L, Lin R, Xu N, Ye J, Sun J, Liu Q (2019) Invasive fungal disease is associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplant: a single center, retrospective study. Infection 47(2):275\u2013284","journal-title":"Infection"},{"key":"5361_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1756-8722-5-46","volume":"5","author":"L Xuan","year":"2012","unstructured":"Xuan L, Huang F, Fan Z, Zhou H, Zhang X, Yu G, Zhang Y, Liu C, Sun J, Liu Q (2012) Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies. J Hematol Oncol 5:46","journal-title":"J Hematol Oncol"},{"issue":"1","key":"5361_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12916-019-1393-7","volume":"17","author":"R Lin","year":"2019","unstructured":"Lin R, Wang Y, Huang F, Fan Z, Zhang S, Yang T, Xu Y, Xu N, Xu L, Ye J, Sun J, Huang X, Liu Q (2019) Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study. Bmc Med 17(1):156","journal-title":"Bmc Med"},{"issue":"1","key":"5361_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, Chanswangphuwana C, Efebera YA, Holler E, Litzow M, Ordemann R, Qayed M, Renteria AS, Reshef R, Woelfl M, Chen Y-B, Goldstein S, Jagasia M, Locatelli F, Mielke S, Porter D, Schechter T, Shekhovtsova Z, Ferrara JLM, Levine JE (2016) International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD international consortium. Biol Blood Marrow Transplant 22(1):4\u201310","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"5361_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng G-S, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers MED (2015) National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 21(3):389\u2013401","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"5361_CR29","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.bbmt.2009.05.019","volume":"15","author":"J Pidala","year":"2009","unstructured":"Pidala J, Kim J, Field T, McBride A, Kharfan-Dabaja M, Perkins J, Fernandez H, Perez L, Ayala E, Anasetti C (2009) Infliximab for managing steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 15(9):1116\u20131121","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"5361_CR30","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.bbmt.2019.04.003","volume":"25","author":"S Abedin","year":"2019","unstructured":"Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Bairn A, Runaas L, Longo W, Drobyski W, Hari PN, Hamadani M (2019) Efficacy, toxicity, and infectious complications in ruxolitinib-treated patients with corticosteroid-refractory graft-versus-host disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant 25(8):1689\u20131694","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"5361_CR31","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41409-019-0731-x","volume":"55","author":"VE Gomez","year":"2020","unstructured":"Gomez VE, Garcia-Gutierrez V, Corral LL, Cadenas IG, Martinez AP, Malaver FJM, Caballero-Velazquez T, Sierra PAG, Alegria MCV, Salinas IMP, Cabrera CC, Vicent MG, Torres NR, Porras RP, Coll CF, Orti G, Ferreiras DV, Llanza RDlC, Moles P, Velazquez-Kennedy K, Mende MJ, Barrigon DC, Perez E, Bofarull RM, Gerosa SS, Sierra J, Poch M, Ripa MTZ, Perez MAD, Angulo BM, Ortega IS, Caballer JS, Gomez JM, Tocino IE, Perez-Simon JA, Geth (2020) Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. Bone Marrow Transplant 55(3):641\u2013648","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"5361_CR32","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/ajh.26475","volume":"97","author":"X-D Mo","year":"2022","unstructured":"Mo X-D, Hong S-D, Zhao Y-L, Jiang E-L, Chen J, Xu Y, Sun Z-M, Zhang W-J, Liu Q-F, Liu D-H, Wan D-M, Mo W-J, Ren H-Y, Yang T, Huang H, Zhang X, Wang X-N, Song X-M, Gao S-J, Wang X, Chen Y, Xu B, Jiang M, Huang X-B, Li X, Zhang H-Y, Wang H-T, Wang Z, Niu T, Wang J-S, Xia L-H, Liu X-D, Li F, Zhou F, Lang T, Hu J, Wu S-J, Huang X-J (2022) Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis. Am J Hematol 97(4):458\u2013469","journal-title":"Am J Hematol"},{"key":"5361_CR33","doi-asserted-by":"crossref","unstructured":"Tan Y, Xiao H, Wu D, Luo Y, Lan J, Liu Q, Yu K, Shi J, He J, Zheng W, Lai X, Zhu Y, Du K, Ye Y, Zhao Y, Zheng G, Hu Y, Han X, Zheng Y, Wei G, Cai Z, Huang H (2017) Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: a multi-center prospective study. Oncoimmunology 6(3):e1277307","DOI":"10.1080\/2162402X.2016.1277307"},{"issue":"2","key":"5361_CR34","doi-asserted-by":"publisher","first-page":"E328","DOI":"10.1634\/theoncologist.2019-0627","volume":"25","author":"D Przepiorka","year":"2020","unstructured":"Przepiorka D, Luo L, Subramaniam S, Qiu J, Gudi R, Cunningham LC, Nie L, Leong R, Ma L, Sheth C, Deisseroth A, Goldberg KB, Blumenthal GM, Pazdur R (2020) FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease. Oncologist 25(2):E328\u2013E334","journal-title":"Oncologist"},{"issue":"6","key":"5361_CR35","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s00280-021-04351-w","volume":"88","author":"N Isberner","year":"2021","unstructured":"Isberner N, Kraus S, Grigoleit GU, Aghai F, Kurlbaum M, Zimmermann S, Klinker H, Scherf-Clavel O (2021) Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice-a prospective single-center trial. Cancer Chemother Pharmacol 88(6):973\u2013983","journal-title":"Cancer Chemother Pharmacol"},{"key":"5361_CR36","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.2147\/DDDT.S338752","volume":"15","author":"C Wei","year":"2021","unstructured":"Wei C, Zhang X, Liang D, Yang J, Du J, Yue C, Deng L (2021) Ruxolitinib for treatment of steroid-refractory graft-versus-host disease: real-world data from Chinese patients. Drug Des Dev Ther 15:4875\u20134883","journal-title":"Drug Des Dev Ther"},{"issue":"6","key":"5361_CR37","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.12998\/wjcc.v8.i6.1065","volume":"8","author":"S-H Dang","year":"2020","unstructured":"Dang S-H, Liu Q, Xie R, Shen N, Zhou S, Shi W, Liu W, Zou P, You Y, Zhong Z-D (2020) Ruxolitinib add-on in corticosteroid-refractory graft-vs-host disease after allogeneic stem cell transplantation: Results from a retrospective study on 38 Chinese patients. World J Clin Cases 8(6):1065\u20131073","journal-title":"World J Clin Cases"},{"issue":"12","key":"5361_CR38","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1182\/blood.V75.12.2459.2459","volume":"75","author":"K Atkinson","year":"1990","unstructured":"Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA, Jacobsen N, Kolb HJ, Rimm AA, Ringden O (1990) Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 75(12):2459\u20132464","journal-title":"Blood"},{"issue":"9674","key":"5361_CR39","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","volume":"373","author":"JLM Ferrara","year":"2009","unstructured":"Ferrara JLM, Levine JE, Reddy P, Holler E (2009) Graft-versus-host disease. Lancet 373(9674):1550\u20131561","journal-title":"Lancet"},{"issue":"26","key":"5361_CR40","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR (2017) Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med 377(26):2565\u20132579","journal-title":"N Engl J Med"},{"issue":"1","key":"5361_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2016-06-686618","volume":"129","author":"KP MacDonald","year":"2017","unstructured":"MacDonald KP, Hill GR, Blazar BR (2017) Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood 129(1):13\u201321","journal-title":"Blood"},{"issue":"1","key":"5361_CR42","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.bbmt.2014.09.030","volume":"21","author":"K Zhao","year":"2015","unstructured":"Zhao K, Lou R, Huang F, Peng Y, Jiang Z, Huang K, Wu X, Zhang Y, Fan Z, Zhou H, Liu C, Xiao Y, Sun J, Li Y, Xiang P, Liu Q (2015) Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 21(1):97\u2013104","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"5361_CR43","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","volume":"123","author":"S Spoerl","year":"2014","unstructured":"Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T, Verbeek M, Fischer J, Otten V, Schmickl M, Maas-Bauer K, Finke J, Peschel C, Duyster J, Poeck H, Zeiser R, von Bubnoff N (2014) Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease. Blood 123(24):3832\u20133842","journal-title":"Blood"},{"issue":"16","key":"5361_CR44","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1158\/1078-0432.CCR-14-2758","volume":"21","author":"C Carniti","year":"2015","unstructured":"Carniti C, Gimondi S, Vendramin A, Recordati C, Confalonieri D, Bermema A, Corradini P, Mariotti J (2015) Pharmacologic inhibition of JAK1\/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects. Clin Cancer Res 21(16):3740\u20133749","journal-title":"Clin Cancer Res"},{"issue":"19","key":"5361_CR45","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1056\/NEJMe2003331","volume":"382","author":"N Chao","year":"2020","unstructured":"Chao N (2020) Finally, a successful randomized trial for GVHD. N Engl J Med 382(19):1853\u20131854","journal-title":"N Engl J Med"},{"issue":"9","key":"5361_CR46","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/s41409-020-0831-7","volume":"55","author":"Y Ru","year":"2020","unstructured":"Ru Y, Zhang X, Song T, Ding Y, Zhu Z, Fan Y, Xu Y, Sun A, Qiu H, Jin Z, Tang X, Han Y, Fu Z, Chen S, Ma X, Chen F, Chen J, Wu D (2020) Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes. Bone Marrow Transplant 55(9):1754\u20131762","journal-title":"Bone Marrow Transplant"},{"key":"5361_CR47","doi-asserted-by":"crossref","unstructured":"Choi J, Cooper ML, Alahmari B, Ritchey J, Collins L, Holt M, DiPersio JF (2014) Pharmacologic blockade of JAK1\/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. Plos One 9(10):e109799","DOI":"10.1371\/journal.pone.0109799"},{"issue":"4","key":"5361_CR48","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1182\/blood.2019000953","volume":"136","author":"T Toubai","year":"2020","unstructured":"Toubai T, Magenau J (2020) Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease. Blood 136(4):429\u2013440","journal-title":"Blood"},{"issue":"3","key":"5361_CR49","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/bjh.17700","volume":"195","author":"S Abedin","year":"2021","unstructured":"Abedin S, Rashid N, Schroeder M, Romee R, Nauffal M, Moustafa MA, Kharfan-Dabaja MA, Palmer J, Hogan W, Hefazi M, Larson S, Holtan S, DeFilipp Z, Jayani R, Dholaria B, Pidala J, Khimani F, Grunwald MR, Butler C, Hamadani M (2021) Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis. Br J Haematol 195(3):429\u2013432","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05361-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05361-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05361-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T11:04:00Z","timestamp":1694257440000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05361-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["5361"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05361-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,20]]},"assertion":[{"value":"23 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}